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Secondary chronic venous disease progresses faster
than primary
Nicos Labropoulos, PhD, DIC, DVT,a Antonios P. Gasparis, MD, RVT,a Dina Pefanis, MBBS,a
Luis R. Leon Jr, MD, RVT,b and Apostolos K. Tassiopoulos, MD,a Stony Brook, NY; and Tucson, Ariz
Purpose: To compare the progression rate of primary with secondary chronic venous disease (CVD).
Methods: Patients with a first episode of proximal deep vein thrombosis (DVT), diagnosed by duplex ultrasound (DU)
were included in group A - secondary CVD (41 patients, 46 limbs). DU was performed at least once, 1 year after the
diagnosis, and repeated at 5 years. Group B - primary CVD (41 patients, 50 limbs) included age- and sex-matched
patients with primary CVD and duration of 5 to 10 years to be comparable with that of group A. They had no history of
DVT and were referred for reflux evaluation. All their veins were free of postthrombotic signs upon DU examination.
Group C (15 patients, 30 limbs) had no signs and symptoms of CVD andwere examined at baseline and 5 years later. This
group of patients was also matched for age and sex. Clinic examinations were performed at 3, 6, and 12months and yearly
thereafter. The CEAP system was used to grade disease severity. The proximal veins were divided in the CFV, FV, and
POPV segments for analysis. Thrombosed veins were subsequently graded as complete, partial, and fully recanalized.
Recurrent DVT cases were also recorded.
Results: At 5-year follow-up, the prevalence of skin damage was significantly higher in group A (11/46 vs group B 3/50,
P .019 and vs group C 0/30, P< .01). The progression to skin damage in group Awas faster as it changed from 4% (2/46)
at 1 year (P  0.014) compared with the two other groups. In group A, 22 limbs had reflux, three had obstruction, 19 had
combine reflux and obstruction, and twowere normal. In groupB, superficial, deep, and perforator vein refluxwere seen in 50,
4, and 15 limbs, respectively. In group C, five limbs in four patients developed superficial reflux in which only two had
symptoms.TheCEAPclass in this groupwasC0N25,C13, andC22. In groupA, skin damagewas significantly higher
in limbs with combined proximal and distal obstruction as well as in limbs with combined reflux and obstruction (P  .012
and P 0.013, respectively). DVTwas found in 108 segments (25 CFV, 40 FV, and in 43 POPV), 82 at the first episode and
26 as an ipsilateral recurrence. Ipsilateral and contralateral recurrences were seen in 21.9% and 9.8% of patients, respectively.
Complete recanalization occurred in 43 segments, partial in 55, and none in 10. Reflux occurred in 85.5% and 60.5% of the
partially and completely recanalized segments, respectively (P  .006).
Conclusions: The progression of CVD is more rapid in postthrombotic limbs when compared with those with primary
CVD. The incidence of CVD in normal individuals is small and its progression is slow. Poor prognostic factors for
progression to advanced CVD include the combination of reflux and obstruction, ipsilateral recurrent DVT, and
multi-segmental involvement. (J Vasc Surg 2009;49:704-10.)Chronic venous disease (CVD) of the lower extremities
is a significant socioeconomic problem, since it incurs a cost
of at least $200million annually to the United States health
care, in addition to causing detriment upon patient quality
of life and disability.1-3 CVD is a consequence of venous
hypertension, which results from reflux, obstruction, or a
combination of both.4,5
Primary CVD is far more common than secondary with
the latter being responsible for about 18% to 28% of limbs
with CVD.6,7 One of the most important causes of venous
outflow obstruction is deep vein thrombosis (DVT).8 Its
incidence is 1 in 1000 people per year. The incidence of
recurrent DVT is 17% at 2 years, 24% at 5 years, and 30% at
8 years.9 Ulceration may ensue, with a cumulative inci-
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704dence of about 4% at 20 years, hence, a common compli-
cation.4 Patients with primary extensive DVT, ipsilateral
recurrent DVT, and insufficient oral anticoagulation are at
higher risk of developing clinically significant CVD.10 Fac-
tors found to affect the onset of secondary CVD were the
event type and site of venous thromboembolism.11
The mean time for ulcers to develop from the moment
of the first diagnosis of CVD is 5 years.12 However, the rate
of CVD progression has not been adequately studied in
primary cases. In addition, no studies have compared pri-
mary with secondary disease in terms of CVD progression.
Our study aimed to assess the severity and rate of progres-
sion in primary compared with secondary CVD.
PATIENTS AND METHODS
This prospective study was performed by selecting pa-
tients assessed in the Vascular Laboratory for DVT, CVD,
and those without venous disease. Three groups were se-
lected for comparison purposes. The first group (group A)
included patients with a documented episode of acute
proximal DVT (popliteal vein or higher). This was the first
lower extremity thrombotic episode in their lives, which
was diagnosed by duplex ultrasound (DU). They also had
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confirm the distribution and extent of reflux and/or ob-
struction, as well as the anatomic distribution. Clinic visits
were scheduled at 3, 6, and 12 months and yearly thereaf-
ter. Clinical and DU examinations were repeated in all
patients at 5 years.
A second group (group B), including age- and sex-
matched patients with primary CVD and duration of dis-
ease of at least 5 years, was also studied. This group was
selected from patients who came to our vascular laboratory
for venous reflux evaluation. They had no previous history
of DVT and all lower extremities had superficial venous
reflux during DU examination. Patients who had post-
thrombotic signs in their veins such as old thrombus,
intraluminal webs, and wall thickening were excluded. The
disease duration was determined by their recollection of
appearance of reticular or varicose veins of their lower
extremities. Patients who were not certain about the onset
of their disease were excluded. Since venous disease starts
before the patients develop signs and symptoms13 of CVD
the disease was present for a longer period of time that
cannot be determined by this study. Therefore, this group
included patients that had similar or longer duration of
disease to those of group A.
The third group (group C) was our control and com-
prised from individuals that had no signs or symptoms of
CVD and were age- and sex-matched with the other two
groups. Also, there was no evidence of reflux or obstruction
on examination by DU. These subjects were selected from
patients that came for another examination and from
friends and our staff. This group had a yearly follow-up and
a final physical examination and DU at 5 years.
Groups B and C were sex-matched with group A by
allowing a smaller difference than five patients between
males and females in each group. These two groups were
alsomatched for age by including similar ranges and amean
value within 5 years from group A.
The advanced CEAP systemwas used to clinically grade
the severity of the disease.14 The superficial and deep
venous systems were evaluated with DU for reflux and
obstruction.13,15 The location and extent of both were
recorded. Recurrent episodes of DVT were noted. Recur-
rent DVT was diagnosed when a thrombus was found in a
new location or when the diameter of a previously throm-
bosed vein segment increased by 2 mm in a subsequent
examination.16 The distribution and extent of obstruction
was evaluated in the supine position. It was graded as
complete, partial, and fully recanalized. Lack of compress-
ibility, filling defects on color mode, and visible luminal
thrombus without any evidence of flow in the vein segment
were used as DU criteria for complete obstruction. Partial
recanalization was defined when a vein was partially com-
pressible with visible luminal thrombus or intraluminal
webs while at least one flow channel was identified with
spontaneous flow or after distal augmentation. Vein seg-
ments that were widely open, which filled with color from
wall to wall with distal augmentation and were completely
compressible, were considered fully recanalized. In occa-sions, vein wall thickening was seen in fully recanalized
veins as a consequence of scarring from the thrombotic
process. These veins were not considered to have anatomic
obstruction. The distribution and extent of reflux was
studied in the standing position. The cut-off values for
reflux were 1 s in the common femoral (CFV), femoral
(FV), and popliteal veins (POPV), 0.5 s in the deep
femoral, deep calf veins, and superficial veins and0.5 s in
the perforating veins.17
All patients were provided and strongly encouraged to
use compression stockings with 30 to 40 mm Hg. Patients
with DVT were treated initially with parenteral anticoagu-
lation followed by oral anticoagulation (INR 2-3) for a
minimum of 6 months. Hypercoagulable work-up was not
available for all patients.
Patients with body mass index (BMI) 35, history of
previous or current malignancy, joint problems, immobil-
ity, inflammation, lymphangitis, lymphedema, CVD prior
to DVT, superficial thrombophlebitis, or DVT prior to the
event in this study, and those with previous interventions in
the lower extremity were excluded from both groups. A
large number of patients with thrombosis were identified;
however, several were excluded because they had at least
one of the exclusion criteria, were unable or chose not to
come for their follow-up, relocated, or died. Patients with
isolated calf DVT were not included as these patients are
part of another ongoing trial related to this pathology
alone.
Statistical analysis. Descriptive statistics were used to
analyze patient’s characteristics in the individual groups.
For continuous data comparisons among the groups were
made with a two-tailed t test. Comparison of proportions
was performed with a 2 test. The Fisher exact test was used
when the expected value in any of the cells was less than 5.
A two-tailed test was applied in both. Statistical significance
was set at .05.
RESULTS
Initially, 115 patients were selected; 50 patients in
group A, 45 in group B, and 20 in group C. However, after
the selection some patients decided not to come for their
follow-up (n  9), moved to another place (n  4),
developed medical problems unrelated to CVD that im-
pacted their outcome (n  3), or died from nonvenous
thromboembolic disease (n  2). Therefore, 97 patients
were available for analysis. The demographic characteristics
of the two groups and control group are seen in the Table I.
Since all three groups were age- and gender-matched,
there were no significant differences among them (P  .3
for age and P  .7 for gender for all comparisons).
The patients in the group A were identified in a period
of 6 months. There were 1235 patients referred for DVT
evaluation of whom 179 were positive (14.5%). Of these,
129 patients were excluded as they did not fulfill the
criteria. In the CVD group, 45 patients were identified in a
5-month period. There were 327 patients referred for CVD
evaluation of which 308 were positive. Of these patients,
263 were excluded as they did not fulfill the criteria. The
linica
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after screening 64 individuals of which 44 were positive and
therefore excluded from the study.
The CEAP classification for both patient groups and
the control, at 5 years is shown in Tables II-IV. In group A,
46 limbs were involved of which 22 had reflux (48%), 19
had reflux and obstruction (41%), 3 had obstruction alone
(6.5%), and 2 were normal (4.5%). As all patients in group
A were selected, no cases of isolated calf DVT were identi-
fied. Twenty-five limbs (54%) had isolated proximal vein
thrombosis and 21 limbs (46%) had combined proximal
and calf DVT. Patients in group B, all belonged to clinical
classes 2 to 4. Because they were selected, all limbs had
reflux and none had obstruction. Reflux in the superficial
veins was detected in all patients of this group, perforator
vein reflux in 30% of limbs, and deep vein reflux was found
in 8% of limbs. In the group C, superficial reflux developed
Table I. Demographic characteristics of patients and cont
Group Sample size Number of males N
Control 15 7
Primary CVD 41 19
Secondary CVD 41 18
CVD, Chronic venous disease; SD, standard deviation.
Table II. Results according to CEAP classification in the
Class Number of limbs Etiology Proxim
0 6* Secondary 6
1 0 Secondary —
2 0 Secondary —
3 29 Secondary 17
4 8 Secondary 2
5 1 Secondary —
6 2 Secondary —
Total 46 25
CVD, Chronic venous disease.
PC: ProximalCalf. RO: RefluxObstruction.*Of the six limbs with c
(9/21 vs 2/25; P  .012). RO vs R or O (8/19 vs 3/25; P  .013).
Table III. Results according to CEAP classification in the
Clinical class Number of limbs Etiology S
0 0 P —
1 0 R —
2 29 I 21
3 18 M 11
4 3 A 1
5 0 R —
6 0 Y —
Total 50 33
S, Superficial veins; P, perforator veins; D, deep veins.only in five of the 30 limbs at 5 years, which is significantlyless compared with group A (P .01). Also, only two of the
limbs developed mild symptoms of itching and burning
sensation.
In group A, the combination of proximal with distal
obstruction and the combination of reflux with obstruction
were more common in limbs with skin damage (CEAP
clinical classes 4-6; P  .012 and P  .013, respectively,
Table II). In addition, when comparing the two study
groups, the prevalence of skin damage was significan-
tly higher in the postthrombotic group (11/46 vs 3/50,
P  .019).
The proximal veins were divided in three anatomic
segments: CFV, FV, and POPV (which, in 46 limbs, ren-
dered a total of 138 proximal vein segments in group A).
When looking at the 5-year DU findings, thrombosis oc-
curred in 108 of those segments: 25 affecting the CFV, 40
the FV, and 43 in the POPV (Table V). Eighty-two were
roup
er of females Number of limbs Mean age (range, SD)
8 30 48 (24-67, SD 14)
22 50 49 (23-81, SD 10)
23 46 51 (21-79, SD 12)
dary CVD (group A)
tomic Pathophysiologic
P  C Reflux Obstruction R  O
— 3 1 —
— — — —
— — — —
12 17 1 11
6 1 1 6
1 — — 1
2 1 — 1
21 22 3 19
l class 0, two were normal. The prevalence of skin damage. PC vs Proximal
ary CVD (group B)
Anatomic
Pathophysiologic
refluxSP SD SPD
— — — —
— — — —
7 1 0 29
5 1 1 18
1 0 1 3
— — — —
— — — —
13 2 2 50rol g
umbsecon
Ana
alprimdetected in the initial event, and 26 as a recurrent ipsilateral
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patients (31.7%) of which in 9 (21.9%) was ipsilateral and 4
(9.8%) contralateral. Complete recanalization occurred in
43 segments, partial in 55, and none in 10. Reflux occurred
in 47 (85.5%) of the segments with partial recanalization
and in 26 (60.5%) of those with complete recanalization
(Table VI; P  .006).
In the group A, the incidence of skin damage at 1 year
was 4% (2/46) whereas at 5 years, it was 24% (11/46) of
limbs (P  .014). Overall from 1 to 5 years, a change in
clinical class occurred in 14 limbs (30%) while 32 limbs
remained the same. Of the limbs that changed three pro-
gressed from class 0 to class 3, nine limbs from class 3 to
class 4 and 6, and two limbs from class 4 to class 5 and 6.
DU of the 14 limbs that had Clinical Class progression
showed either recurrent DVT or progression of reflux in 11
limbs (79%). In the 32 limbs with no progression, DU
showed only reflux changes in 8 (P .001). In the group B,
the skin damage in the three patients occurred in the last 2
years and none had it in the beginning of their disease. In
the group C, reticular veins developed in two limbs at 3
years and in one limb at 5 years, whereas varicose veins were
seen one at 4 and one at 5 years. All these were superficial
veins with reflux. These were tributaries of the saphenous
veins (n  4) and one in a nonsaphenous superficial vein.
The incidence of skin changes was significantly greater in
group A compared with group B (P  .019) and group C
(P  .005).
DISCUSSION
Recent work from our group has shown the effects of
Table IV. Results according to CEAP classification in the
Clinical
class
Number of
limbs Etiology S
0 25 — 0
1 3 Primary 3
2 2 Primary 2
3 0 — 0
4 0 — 0
5 0 — 0
6 0 — 0
Total 30 5
S, Superficial veins; P, perforator veins; D, deep veins.
Table V. Five-year follow-up ultrasound results
of thrombosed vein segments
Recanalization CFV % FV % POPV %
None 2 8 4 10 4 9.3
Partial 13 52 21 52.5 21 48.8
Complete 10 40 15 37.5 18 41.9
Total 25 100 40 100 43 100
CFV, Common femoral vein; FV, femoral vein; POPV, popliteal vein.superficial reflux in the deep veins,18 the progression ofreflux in superficial veins,19 and the mechanisms of reflux
progression in the perforating veins20 in patients with pri-
mary CVD. However, no study has correlated the progres-
sion in primary vs secondary disease, which formed the
rationale of this article. The current investigation demon-
strated that CVD progressed more rapidly in postthrom-
botic limbs than those with primary disease, since the
former had four times higher prevalence of skin damage.
This progression is even more dramatic compared with an
age- and sex-matched control group.
In the primary CVD group, the superficial venous
systemwas the most common etiology of early CVD.While
the reported incidence of deep venous reflux in primary
disease is 22%,18 the contribution of deep venous reflux in
this study was only 8%. This we believe is related to the
duration of disease, since our primary group was selected to
have duration of objective signs or symptoms of 5 years.
Progression of primary disease may take years before in-
volvement of the deep system and development of ad-
vanced clinical symptoms occurs.
In the early stages of primary CVD, it has been shown
that saphenous reflux may be of limited extent with less
involvement of their junctions. With progression of disease,
the extent of superficial reflux increases resulting in junc-
tional and even deep venous reflux.19,21,22 As prevalence of
deep venous reflux increases, CVD worsens and combined
superficial and deep venous reflux is seen with more ad-
vanced clinical class.18 Treatment of the superficial veins in
this situation has been shown to eliminate deep vein reflux
in90% of limbs with primary disease.23,24 Superficial vein
rol (group C)
Anatomic
Pathophysiologic
refluxP SD SPD
0 0 0 0
0 0 0 3
0 0 0 2
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 5
Table VI. Five-year follow-up ultrasound results
of thrombosed vein segments and their relation
with development of reflux
Recanalization Number % Reflux %
None 10 9.3 0 0
Partial 55 50.9 47 85.5
Complete 43 39.8 26 60.5
Total 108 100 73
Incidence of reflux in segments with part.cont
Sinvolvement in our work was more often seen in all classes,
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nates most often in the superficial system and significantly
contributes in the development of symptoms and signs.
Advanced CVD (C4-C6) in our study occurred in 24%
of limbs following DVT at 5 years, which is four times
higher compared with the primary group (11/46 vs 3/50,
P .019). This is in agreement with the results reported by
Prandoni and colleagues,9 who by studying 355 consecu-
tive patients with a first episode of venography-confirmed
DVT, showed a skin damage cumulative incidence of 22.8%
after 2 years, and 28% after 5 years. This incidence did not
significantly change thereafter, with a follow-up as long as 8
years. Meissner et al25 longitudinally studied the natural
history of 68 patients (73 limbs) with a first diagnosis of
lower limb DVT. They used clinical and DU follow-up
(mean 55  26 months) showing a 21% prevalence of skin
damage.
The two consequences of DVT that contribute to the
development of CVD are the presence of thrombus, caus-
ing outflow obstruction and reflux caused by valve damage.
A combination of obstruction and reflux appears to be
clearly associated with severity of symptoms. Johnson et al4
studied acute DVT in 83 limbs of 78 patients with a median
follow-up time of 3 years. Reflux or obstruction alone led to
mild or no symptoms, while the combination of reflux and
obstruction increased the odds by 3.5 times of developing
postthrombotic syndrome. Neglen et al26 analyzed 447
limbs in 429 patients suffering of venous outflow obstruc-
tion. Again, the presence of both reflux and obstruction
produced more severe signs and symptoms of CVD com-
pared with obstruction alone (CEAP class 4-6, 53% vs 24%;
P  .001). Active ulcers in limbs with the combination
were seen in 24%, compared with 3% in those with obstruc-
tion alone (P .001). The data from both studies correlate
well with our findings, which showed that limbs with
combined reflux and obstruction had a higher incidence of
skin damage compared with limbs with reflux or obstruc-
tion alone (8/19 vs 3/25; P  .013). It appears that the
presence of both reflux and obstruction have a good pre-
dictive value for clinical deterioration.
Location and extent of DVTmay also play a role on the
progression of disease. Limbs with both proximal and calf
veins involvement were more often associated with skin
damage (9/11) than isolated, proximal thrombosis (2/11;
P  0.01). Janssen et al27 reported a reduced risk of
postthrombotic syndrome after distal DVT than after a
more proximally located thrombus. Others have not found
that association. Prandoni and colleagues9 could not find a
relationship between the extent of initial DVT (hazard ratio
1.1) or degree of occlusion (hazard ratio 0.8) and the risk of
developing postthrombotic syndrome. Ziegler et al10 in a
study with at least 10-year follow-up did not find a relation-
ship between clinical severity and proximity of the throm-
botic event. However, there was a tendency to develop
more severe postthrombotic syndrome with four-level
DVT and calf vein thrombosis. Yamaki and Nozaki28 pro-
spectively evaluated 70 limbs with DU-confirmed acute
DVT. With serial DU follow-up, they reported that pa-tients with isolated segmental DVT rarely develop CVD, as
opposed to multi-segment DVT, which is in agreement
with our study. It is likely that thrombus lysis in a single vein
segment may more often lead to partial or complete recan-
alization, compared with multiple segments. The latter had
a significantly higher incidence of deep vein reflux at 1 year
(7/35 patients vs 15/35, respectively; P  .01).28
Although there are many natural history studies on
DVT reporting clinical outcome at long term, detailed
results with DU are limited to 1 year. In our study, DU
findings were obtained at 5 years. Complete obstruction
occurred in 9.3% (10/108 thrombosed segments). Partial
(50.9%; 55/108) and complete recanalization (39.8%; 43/
108) were far more common (Table V). The response of
the different anatomic vein segments to the presence of
thrombi has been shown to be different. An accurate anal-
ysis of this response is difficult due to the variability of
definitions used to classify veins as recanalized, partially
occluded, or completely thrombosed. However, two stud-
ies used the same definitions and analysis as ours.
O’Shaughnessy and Fitzgerald29 found a 1-year rate of
thrombi resolution of 78% in the CFV, 42% in the FV, and
54% in the POPV. Yamaki et al 28 found 68%, 49%, and 81%
for the same areas, respectively. Our study identified for
5-year complete recanalization rates, 40%, 37.5%, and 42%
for the same areas respectively, which was in agreement
with the previously reported results. Partial resolution was
seen in 52%, 52.5%, and 48.8%; and no resolution in 8%,
10%, and 9.3% in the same areas, respectively. The reason
for the differences in complete recanalization in our study
may be the significantly longer follow-up and the subse-
quent recurrent thrombotic events.
Thirteen out of 41 patients were found to have a
thrombotic recurrence on follow-up (31.7%; nine recurrent
ipsilateral and four contralateral). This occurrence corre-
lates with that of Prandoni and colleagues,9 who reported a
cumulative incidence of recurrent venous thromboembo-
lism of 24.6% (95% CI  19.6% to 29.7%) after 5 years of
follow-up. Recurrent ipsilateral thrombosis was more pre-
dictive of skin damage, with an odds ratio of 5.3 (95% CI
1.2-24.2) with respect to a solitary event (P  .001),
analogous with the findings of Prandoni et al9 (hazard ratio
of 6.4) and Ziegler et al.10 This emphasizes the importance
of primary and secondary prevention, sufficient anticoagu-
lation, control of risk factors, and the use of compression
stockings, the latter furthermore preventing the deteriora-
tion of existing CVD.30
In the group A, the incidence of skin damage at 1 year
was 4% and at 5 years 24%, whereas in the group B, it was
6%. In group C, no patient developed skin damage at 5
years. Secondary CVD appears to progress more rapidly
than primary. The etiologic factors for this may be the
following. During thrombosis, often multiple deep veins
are affected in a short period of time. In contrast, progres-
sion of disease to multiple segments and involvement of the
deep system occurs over longer periods of time in primary
CVD. Repeated hits in the deep veins can further damage
the deep system resulting in accelerated progression. At the
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contributing further. In normal limbs, venous disease de-
velops slowly and skin changes are seen in the first 5 years
due to the limited extension of CVD.
The acceleration of disease in postthrombotic limbs
may also be explained from the underlying pathology. In
primary disease, the main contributing pathology is reflux,
while in postthrombotic limbs in many occasions reflux is
combined with outflow obstruction, which contributes to
higher venous hypertension and may lead to faster progres-
sion of disease.5
Another reason may be that the refluxing blood from
the superficial veins can be accommodated by the normal
deep veins in the primary group. In postthrombotic limbs
where the deep system is affected, the venous return is
much more limited as the capacity of the superficial veins is
significantly smaller compared with the deep veins.31
It has been shown that fibrin is a very potent chemoat-
tractant contributing significantly to the development of
inflammation and eventual skin damage.32 This process is
long-standing in patients with primary disease.18 However,
in vein thrombosis inflammation is acute and more exten-
sive and may contribute to accelerated progression.
Initial results on the use of thrombolysis for DVT were
discouraged from high complication rate with bleeding.33
Current localized treatment with use of mechanical devises
has not only further improved technical results, but have
also decreased incidence of bleeding complications.34-36
Currently, thrombolysis is accepted as a treatment option
for iliofemoral DVT and has been included as such in the
current eighth ACCP guidelines.37
Treatment of DVT in the acute phase with pharmaco-
mechanical thrombolysis (PhMT) has significantly im-
proved not only short-term but also mid-term results.
Recent work from our group38 showed that PhMT in
treatment of iliofemoral DVT resulted in improved out-
comes at a median follow-up of 24 months (13-69
months). Alteration in the progression of CVD in patients
with postthrombotic limbs may justify more aggressive
treatment of femoral-popliteal DVT with thrombolysis in
an attempt to delay the natural history in these patients.
Limitations. In attempting to eliminate possible
other factors that may contribute to progression of CVD,
we encountered our first limitation of this study. The small
sample size of patients does not allow reliable sub-analysis
of patients with leg ulcers. In addition, there may have been
a selection bias so the sample may not be representative of
the population of CVD. A longer term study with a statis-
tically representative sample of adequate power would be
ideal. Another example of the impact of the low sample size
of the study is the wide range of confidence intervals in the
analysis of the likelihood of skin damage and recurrent
ipsilateral thrombosis. However, the trends are very clear
and warrant larger prospective studies for confirmation.
The sample size of the control group was also small,
and it is possible that a different progression rate may have
had occurred in a larger sample. Nevertheless, the differ-
ence in the progression rate between the control group andthe study groups was very significant to cast any doubt in
our findings.
The role of hypercoagulability, anticoagulation, and
recurrent DVT on the development of postthrombotic
syndrome could not be determined in this study because of
the small sample size. Data on family history of VTE and
CVD, type of work, lifestyle, height, and weight, were
collected but their analysis in this study setting was not
meaningful.
While the use of compression stockings was recom-
mended and encouraged, data on patient compliance was
not recorded in this study. Additionally, the use of gradu-
ated compression stockings (albeit highly variable) would
have delayed the development of more severe CVD and so
the follow-up period of 5 years may have been insufficient
to identify severe CVD. Whilst comparing our results with
other studies, discrepancies may be attributed to different
outcome measures and study designs.
Although we excluded patients with BMI35, obesity
may have been a confounding factor to the development of
CVD in this study, since a retrospective report on young
women showed a BMI above 22 kg/m2 was correlated
with a fivefold higher risk of developing CVD.39 In fact,
Padberg and colleagues40 found that two thirds of patients
with class III obesity had severe limb symptoms, typical of
vein disease, without anatomic evidence of venous abnor-
malities. This suggests that obesity itself contributes to the
limb morbidity.
Another limitation for our study was to solely rely on
anatomic terms to define obstruction. The physiological
impact of the venous obstruction was not known and
therefore not included. Finally, the lack of physiologic
testing in this study did no allow us to evaluate the role of
calf muscle pump dysfunction41 between the groups.
CONCLUSIONS
CVD is a multifactorial disease process, but available
natural history studies on DVT have included all patients.
This is the first study that has attempted to exclude possible
contributing factors to the progression of CVD. In addi-
tion, this is the first study to demonstrate that secondary
disease progresses faster than primary. The incidence of
CVD in normal individuals within 5 years is low with
minimal progression. Prognostic factors for worsening of
CVD include the combination of reflux and obstruction,
ipsilateral recurrent DVT, and multi-segmental involve-
ment.
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